The United States Food and Drug Administration (FDA) has granted approval for a gene-editing treatment designed for sickle cell patients aged 12 and above. The announcement, made through an FDA press release on Saturday, introduces two stages of treatment named … Continue reading FDA greenlights historic gene-editing treatment for sickle cell patients in the U.S